ODI Pharma AB (publ) (NGM:ODI)
Sweden · Delayed Price · Currency is SEK 2.260
-0.080 (-3.42%)
At close: Sep 3, 2026
ODI Pharma AB Revenue
In the fiscal year ending June 30, 2026, ODI Pharma AB had annual revenue of 32.92M SEK with 950.33% growth. ODI Pharma AB had revenue of 3.20M in the quarter ending June 30, 2026, with 4,535.02% growth.
Revenue
32.92M
Revenue Growth
+950.33%
P/S Ratio
1.26
Revenue / Employee
32.92M
Employees
1
Market Cap
41.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 32.92M | 29.78M | 950.33% |
| Jun 30, 2025 | 3.13M | -19.15M | -85.94% |
| Jun 30, 2024 | 22.29M | 22.15M | 15,880.34% |
| Jun 30, 2023 | 139.46K | -173.48K | -55.44% |
| Jun 30, 2022 | 312.94K | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transfer Group AB | 184.65M |
| ABAS Protect AB | 91.93M |
| Jumpgate AB | 42.69M |
| GreenMerc AB | 17.24M |
| LightAir AB | 14.43M |
| Kvix AB | 13.01M |
| Zoomability Int AB | 5.67M |
| Synexo Group AB | 2.81M |
ODI Pharma AB News
- 8 days ago - ODI Pharma AB Quarterly report: Q4 2026 - Filings
- 3 months ago - ODI Pharma AB Quarterly report: Q3 2026 - Filings
- 6 months ago - ODI Pharma AB Quarterly report: Q2 2026 - Filings
- 9 months ago - ODI Pharma AB Quarterly report: Q1 2026 - Filings